Predictors of clinically significant quality of life impairment in Parkinson's disease


Por: Garcia, DS, Fonticoba, TD, Cores, C, Munoz, G, Gonzalez, JMP, Miro, CM, Suarez, E, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Catalan, MJ, Nogueira, V, Puente, V, de Arcos, MR, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Clavero, P, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, Mir, P

Publicada: 16 dic 2021
Resumen:
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R-2 = 0.655). An increase in >= 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.

Filiaciones:
Garcia, DS:
 Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain

Fonticoba, TD:
 Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain

Cores, C:
 Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain

Munoz, G:
 Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain

Gonzalez, JMP:
 Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain

Miro, CM:
 Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain

Suarez, E:
 Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain

Jesus, S:
 CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain

 Univ Seville, Unidad Trastornos Movimiento, Serv Neurol & Neurofisiol Clin,CSIC, Inst Biomed Sevilla,Hosp Univ Virgen del Rocio, Seville, Spain

Aguilar, M:
 Hosp Univ Mutua Terrassa, Barcelona, Spain

Pastor, P:
 Hosp Univ Mutua Terrassa, Barcelona, Spain

Planellas, L:
 Clin Pilar, Neurol, Barcelona, Spain

Cosgaya, M:
 Hosp Clin Barcelona, Barcelona, Spain

Caldentey, JG:
 Ctr Neurol Oms 42, Palma de Mallorca, Spain

Caballol, N:
 Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain

Legarda, I:
 Hosp Univ Son Espases, Palma De Mallorca, Spain

Vara, JH:
 Hosp Univ Vall dHebron, Barcelona, Spain

Cabo, I:
 Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain

Manzanares, LL:
 Hosp Univ La Princesa, Madrid, Spain

Aramburu, IG:
 CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain

 Hosp Univ Marques de Valdecilla, Santander, Spain

Rivera, MAA:
 Hosp Gen Hospitalet, Consorci Sanitari Integral, Barcelona, Spain

Catalan, MJ:
 Hosp Univ Clin San Carlos, Madrid, Spain

Nogueira, V:
 Hosp Costa, Lugo, Spain

Puente, V:
 Hosp del Mar, Barcelona, Spain

de Arcos, MR:
 Hosp Univ Virgen Macarena, Seville, Spain

Borrue, C:
 Hosp Infanta Sofia, Madrid, Spain

Vila, BS:
 Inst Assistencia Sanitaria IAS, Inst Catala Salut, Girona, Spain

Sauco, MA:
 Hosp Gen Univ Elche, Elche, Spain

Vela, L:
 Fdn Hosp Alcorcon, Madrid, Spain

Escalante, S:
 Hosp Tortosa Verge de la Cinta HTVC, Tarragona, Spain

Cubo, E:
 Complejo Asistencial Univ Burgos, Burgos, Spain

Padilla, FC:
 Hosp Univ Canarias, San Cristobal La Laguna, Santa Cruz De T, Spain

Castrillo, JCM:
 Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain

Alonso, PS:
 Hosp Univ Puerta de Hierro, Madrid, Spain

Losada, MGA:
 Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain

Ariztegui, NL:
 Complejo Hosp Toledo, Toledo, Spain

Gaston, I:
 Complejo Hosp Navarra, Pamplona, Spain

Clavero, P:
 Complejo Hosp Navarra, Pamplona, Spain

Kulisevsky, J:
 CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain

 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Estrada, MB:
 Hosp Univ Cent Asturias, Oviedo, Spain

Seijo, M:
 Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain

Martinez, JR:
 Hosp Univ Donostia, San Sebastian, Spain

Valero, C:
 Hosp Arnau Vilanova, Valencia, Spain

Kurtis, M:
 Hosp Ruber Int, Madrid, Spain

de Fabregues, O:
 Hosp Univ Vall dHebron, Barcelona, Spain

Ardura, JG:
 Hosp Univ Cabuenes, Gijon, Spain

Ordas, C:
 Hosp Rey Juan Carlos, Madrid, Spain

Diaz, LML:
 Complejo Hosp Univ Orense CHUO, Orense, Spain

McAfee, D:
 Univ Penn, Philadelphia, PA 19104 USA

Martinez-Martin, P:
 CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain

Mir, P:
 CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain

 Univ Seville, Unidad Trastornos Movimiento, Serv Neurol & Neurofisiol Clin,CSIC, Inst Biomed Sevilla,Hosp Univ Virgen del Rocio, Seville, Spain
ISSN: 23738057
Editorial
NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Alemania
Tipo de documento: Article
Volumen: 7 Número: 1
Páginas:
WOS Id: 000730934900001
ID de PubMed: 34916528
imagen Green Published, gold

MÉTRICAS